Develops experimental medicines for patients with cardiometabolic diseases and eye conditions, using human aging research to identify drug targets.
10-K for FY2025, filed Mar 24, 2026We are a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology…View ↗
We intend to advance BGE-102 in two therapeutic areas: cardiometabolic disease and ophthalmology.View ↗
Our second therapeutic area for BGE-102 is ophthalmology. Diabetic macular edema (DME) is our first proof-of-concept indication in this…View ↗
Collaboration partners pay upfront and option fees and fund research or development work; agreements may also provide milestone payments and royalties on future product sales.
10-K for FY2025, filed Mar 24, 2026
$9M
10-K for FY2025, filed Mar 24, 2026
$9M ↗
BioAge works with pharmaceutical collaborators, including Lilly and Novartis, through drug-development and target-discovery collaborations.
10-K for FY2025, filed Mar 24, 2026We are also advancing earlier stage platform-derived programs in collaboration with Eli Lilly and Company (Lilly), and have an ongoing…View ↗
10-K for FY2025, filed Mar 24, 2026
As of December 31, 2025, one customer accounted for 100% of the Company’s accounts receivable. For the year ended December 31, 2025, the…View ↗
No. It lost $80.6M in FY2025.
Competes with Ventyx Biosciences, NodThera, Roche, Merck, Novo Nordisk, AstraZeneca, Neumora, Ventus, Tenvie, Insilico, Brenig, Zydus, Structure Therapeutics, Bristol Myers Squibb, APIE Therapeutics, and Sanofi
10-K for FY2025, filed Mar 24, 2026Many of our current or potential competitors, either alone or with their collaboration partners, have significantly greater financial…View ↗
Loading...